Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

G C Donaldson, T A R Seemungal, A Bhowmik, J A Wedzicha, G C Donaldson, T A R Seemungal, A Bhowmik, J A Wedzicha

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is characterised by both an accelerated decline in lung function and periods of acute deterioration in symptoms termed exacerbations. The aim of this study was to investigate whether these are related.

Methods: Over 4 years, peak expiratory flow (PEF) and symptoms were measured at home daily by 109 patients with COPD (81 men; median (IQR) age 68.1 (63-74) years; arterial oxygen tension (PaO(2)) 9.00 (8.3-9.5) kPa, forced expiratory volume in 1 second (FEV(1)) 1.00 (0.7-1.3) l, forced vital capacity (FVC) 2.51 (1.9-3.0) l); of these, 32 (29 men) recorded daily FEV(1). Exacerbations were identified from symptoms and the effect of frequent or infrequent exacerbations (> or < 2.92 per year) on lung function decline was examined using cross sectional, random effects models.

Results: The 109 patients experienced 757 exacerbations. Patients with frequent exacerbations had a significantly faster decline in FEV(1) and peak expiratory flow (PEF) of -40.1 ml/year (n=16) and -2.9 l/min/year (n=46) than infrequent exacerbators in whom FEV(1) changed by -32.1 ml/year (n=16) and PEF by -0.7 l/min/year (n=63). Frequent exacerbators also had a greater decline in FEV(1) if allowance was made for smoking status. Patients with frequent exacerbations were more often admitted to hospital with longer length of stay. Frequent exacerbations were a consistent feature within a patient, with their number positively correlated (between years 1 and 2, 2 and 3, 3 and 4).

Conclusions: These results suggest that the frequency of exacerbations contributes to long term decline in lung function of patients with moderate to severe COPD.

References

    1. Eur Respir J. 1999 Nov;14(5):1015-22
    1. Chest. 1999 Jul;116(1):40-6
    1. Thorax. 2000 Feb;55(2):114-20
    1. Chest. 2000 Mar;117(3):662-71
    1. BMJ. 2000 May 13;320(7245):1297-303
    1. Am J Respir Crit Care Med. 2000 May;161(5):1608-13
    1. Am J Med. 2000 Sep;109(4):288-95
    1. Am J Respir Crit Care Med. 2001 Apr;163(5):1256-76
    1. Am J Respir Crit Care Med. 2001 Aug 1;164(3):358-64
    1. Am J Respir Crit Care Med. 2001 Sep 15;164(6):1002-7
    1. Am J Respir Crit Care Med. 2001 Nov 1;164(9):1618-23
    1. Thorax. 2002 Sep;57(9):759-64
    1. Am J Med. 1979 Jul;67(1):44-50
    1. Ann Intern Med. 1987 Feb;106(2):196-204
    1. Thorax. 1994 Apr;49(4):364-6
    1. Am J Respir Crit Care Med. 1996 May;153(5):1530-5
    1. Chest. 1996 May;109(5):1156-62
    1. Prev Med. 1997 Jul-Aug;26(4):418-21
    1. Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1418-22
    1. Am J Respir Crit Care Med. 1998 Oct;158(4):1277-85
    1. Eur Respir J. 1999 Feb;13(2):338-42
    1. Eur Respir J. 1999 Feb;13(2):343-8

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj